[{"orgOrder":0,"company":"Catherine Anne Chappell","sponsor":"Gilead Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Sofosbuvir","moa":"Hepatitis C virus NS5B RNA-dependent RNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Catherine Anne Chappell","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Catherine Anne Chappell \/ Gilead Sciences","highestDevelopmentStatusID":"11","companyTruncated":"Catherine Anne Chappell \/ Gilead Sciences"},{"orgOrder":0,"company":"Catherine Anne Chappell","sponsor":"Gilead Sciences | Gansu Provincial Maternal and Child Health Care Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Sofosbuvir","moa":"Hepatitis C virus NS5B RNA-dependent RNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Catherine Anne Chappell","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Catherine Anne Chappell \/ Gilead Sciences | Gansu Provincial Maternal and Child Health Care Hospital","highestDevelopmentStatusID":"11","companyTruncated":"Catherine Anne Chappell \/ Gilead Sciences | Gansu Provincial Maternal and Child Health Care Hospital"},{"orgOrder":0,"company":"AIDS Clinical Trials Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Sofosbuvir","moa":"||Hepatitis C virus NS5B RNA-dependent RNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"AIDS Clinical Trials Group","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AIDS Clinical Trials Group \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"AIDS Clinical Trials Group \/ Inapplicable"},{"orgOrder":0,"company":"Columbia University","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Sofosbuvir","moa":"Hepatitis C virus NS5B RNA-dependent RNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Columbia University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Columbia University \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Columbia University \/ Inapplicable"}]

Find Clinical Drug Pipeline Developments & Deals for Sofosbuvir

Sofosbuvir
Drugs in Dev.
Full Screen View

Weekly News Recap
#Phispers

Stock Recap
#PipelineProspector

cayman pipeline prospector

Contact Supplier

Check COS database
Check all USDMF suppliers

Contact Us
PharmaScopic.com

Sofosbuvir

ACCESS ALL DATA, CHEMISTRY

ACTIVE PHARMA INGREDIENTS

38 API Suppliers, 9 USDMF, 6 EU WC, 3 KDMF, 7 NDC API, 26 Listed Suppliers, $ API Reference Price

DEVELOPMENTS

186 Drugs in Development

186 Drugs in Development

INTERMEDIATES

12 Intermediate Suppliers

12 Intermediate Suppliers

FINISHED DOSAGE FORMULATIONS

42 FDF Dossiers, 14 FDA Orange Book, 6 Europe, 4 Canada, 2 South Africa, 16 Listed Dossiers

RELATED EXCIPIENT COMPANIES

1 Rochem International Inc, 14 SPI Pharma, 4 DKSH, 2 Boai NKY Pharmaceuticals Ltd, 5 Gangwal Healthcare, 2 Nanjing Well Pharmaceutical, 1 Pfanstiehl, 4 Actylis, 1 Aeon Procare, 1 Alcedo Pharmachem, 5 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd, 12 BASF, 5 Corel Pharma Chem, 5 DFE Pharma, 1 Esteem Industries, 1 Finar, 7 Gangwal Chemicals, 1 Huzhou Sunflower Pharmaceutical, 2 Ideal Cures, 2 Ingredion Pharma Solutions, 14 Kerry, 2 Keval Exports, 12 Microlex e.U, 2 Nitika Pharmaceutical Specialities, 2 Nomisma Healthcare, 2 Novo Excipients, 1 Pharmatrans-Sanaq, 4 Pluviaendo, 3 Prachin Chemical, 13 Roquette, 4 Shanghai Shenmei Pharmaceutical Technology Co., Ltd, 1 Shijiazhuang Huaxu Pharmaceutical, 10 Sigachi Industries, 3 Silverline Chemicals, 3 Vasa Pharmachem

EXCIPIENTS BY APPLICATIONS

51 Fillers, Diluents & Binders, 26 Direct Compression, 20 Coating Systems & Additives, 19 Granulation, 18 Disintegrants & Superdisintegrants, 14 Controlled & Modified Release, 14 Chewable & Orodispersible Aids, 14 Thickeners and Stabilizers, 13 Taste Masking, 13 Lubricants & Glidants, 10 Topical, 10 Co-Processed Excipients, 8 Film Formers & Plasticizers, 7 Solubilizers, 7 Parenteral, 3 Coloring Agents, 3 Emulsifying Agents, 2 API Stability Enhancers, 2 Rheology Modifiers

DIGITAL CONTENT

272 News #PharmaBuzz

272 News #PharmaBuzz

GLOBAL SALES INFORMATION

6 US Medicaid Prescriptions, 7 Regulatory FDF Prices, 26 Annual Reports

MARKET PLACE

20 APIs, 1 FDF Dossiers

PATENTS & EXCLUSIVITIES

358 US Patents, 23 US Exclusivities, 12 Health Canada Patents

REF. STANDARDS & IMPURITIES

1 Others

1 Others

Xls

Filters

×

filter

Company Name

filter

Year

filter

DEALS // DEV.

filter

Country

filter

Sponsor

filter

Therapeutic Area

filter

Study Phase

filter

Deal Type

filter

Product Type

filter

Dosage Form

filter

Lead Product

filter

Target

All Developments

Therapeutic Area by Lead Product

Study Phase by Lead Product

Company by Lead Product

Top Deals by Deal Size (USD bn)

Reset All

01

AbbVie Inc

U.S.A

Coatings Trends

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Lead Product(s) : Sofosbuvir

Therapeutic Area : Infections and Infectious Diseases

Study Phase : Phase III

Sponsor : Inapplicable

Deal Size : Inapplicable

Deal Type : Inapplicable

Efficacy and Safety of Glecaprevir (ABT-493)/Pibrentasvir (ABT 530) (GLE/PIB) in Combination With Sofosbuvir a...

Details : Undisclosed

Product Name : Undisclosed

Product Type : Other Small Molecule

Upfront Cash : Inapplicable

October 20, 2016

Lead Product(s) : Sofosbuvir

Therapeutic Area : Infections and Infectious Diseases

Highest Development Status : Phase III

Sponsor : Inapplicable

Deal Size : Inapplicable

Deal Type : Inapplicable

Abbvie Company Banner

Stock Recap
#PipelineProspector

Data Compilation
#PharmaFlow

02

AIDS Clinical Trials Group

Country

Coatings Trends

Not Confirmed

03

Catherine Anne Chappell

Country

Coatings Trends

Not Confirmed

04

Columbia University

U.S.A

Coatings Trends

Not Confirmed

05

Catherine Anne Chappell

Country

Coatings Trends

Not Confirmed

06

Gilead Sciences

U.S.A

Coatings Trends

Not Confirmed

07

Gilead Sciences

U.S.A

Coatings Trends

Not Confirmed

08

University of Pennsylvania

Country

Coatings Trends

Not Confirmed

09

University of California, San Francisco

Country

Coatings Trends

Not Confirmed

10

Jennifer Havens

Country

Coatings Trends

Not Confirmed